SMT202100401T1 - Roditori umanizzati che esprimono catene pesanti contenenti comini vl - Google Patents

Roditori umanizzati che esprimono catene pesanti contenenti comini vl

Info

Publication number
SMT202100401T1
SMT202100401T1 SM20210401T SMT202100401T SMT202100401T1 SM T202100401 T1 SMT202100401 T1 SM T202100401T1 SM 20210401 T SM20210401 T SM 20210401T SM T202100401 T SMT202100401 T SM T202100401T SM T202100401 T1 SMT202100401 T1 SM T202100401T1
Authority
SM
San Marino
Prior art keywords
domains
heavy chains
chains containing
express heavy
humanized rodents
Prior art date
Application number
SM20210401T
Other languages
English (en)
Italian (it)
Inventor
Lynn Macdonald
Sean Stevens
Cagan Gurer
Andrew J Murphy
Karolina A Meagher
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of SMT202100401T1 publication Critical patent/SMT202100401T1/it

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/462—Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24046—Adamalysin (3.4.24.46)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/10—Immunoglobulin or domain(s) thereof as scaffolds for inserted non-Ig peptide sequences, e.g. for vaccination purposes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/20—Pseudochromosomes, minichrosomosomes
    • C12N2800/204—Pseudochromosomes, minichrosomosomes of bacterial origin, e.g. BAC
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Environmental Sciences (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Husbandry (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Housing For Livestock And Birds (AREA)
  • Central Heating Systems (AREA)
SM20210401T 2012-02-01 2013-02-01 Roditori umanizzati che esprimono catene pesanti contenenti comini vl SMT202100401T1 (it)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261593463P 2012-02-01 2012-02-01
US201261677538P 2012-07-31 2012-07-31
EP19191081.9A EP3597038B1 (en) 2012-02-01 2013-02-01 Humanized rodents that express heavy chains containing vl domains

Publications (1)

Publication Number Publication Date
SMT202100401T1 true SMT202100401T1 (it) 2021-09-14

Family

ID=47714588

Family Applications (2)

Application Number Title Priority Date Filing Date
SM20190685T SMT201900685T1 (it) 2012-02-01 2013-02-01 Topi umanizzati che esprimono catene pesanti contenenti domini vl
SM20210401T SMT202100401T1 (it) 2012-02-01 2013-02-01 Roditori umanizzati che esprimono catene pesanti contenenti comini vl

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SM20190685T SMT201900685T1 (it) 2012-02-01 2013-02-01 Topi umanizzati che esprimono catene pesanti contenenti domini vl

Country Status (26)

Country Link
US (3) US20130212719A1 (enExample)
EP (3) EP2809150B1 (enExample)
JP (6) JP2015505477A (enExample)
KR (2) KR20140123983A (enExample)
CN (2) CN106117364B (enExample)
AU (3) AU2013204758B2 (enExample)
BR (1) BR112014018843B1 (enExample)
CA (1) CA2863175A1 (enExample)
CY (2) CY1122419T1 (enExample)
DK (2) DK3597038T3 (enExample)
ES (2) ES2753774T3 (enExample)
HR (2) HRP20192218T1 (enExample)
HU (2) HUE055610T2 (enExample)
IL (3) IL233827A0 (enExample)
LT (2) LT2809150T (enExample)
ME (1) ME03611B (enExample)
MX (2) MX373286B (enExample)
NZ (5) NZ734504A (enExample)
PL (2) PL3597038T3 (enExample)
PT (2) PT2809150T (enExample)
RS (2) RS59699B1 (enExample)
RU (2) RU2664185C2 (enExample)
SG (3) SG10201606256TA (enExample)
SI (2) SI2809150T1 (enExample)
SM (2) SMT201900685T1 (enExample)
WO (1) WO2013116609A1 (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2669298A3 (en) * 2008-05-23 2014-02-26 Ablexis, LLC Single variable immunoglobulin domain comprising VL-DH-JL
ES2948572T3 (es) 2009-07-08 2023-09-14 Kymab Ltd Modelos de roedores y moléculas terapéuticas
US9445581B2 (en) 2012-03-28 2016-09-20 Kymab Limited Animal models and therapeutic molecules
IL315833A (en) * 2010-08-02 2024-11-01 Regeneron Pharma Mice producing binding proteins containing VL regions
IL273982B2 (en) 2011-08-05 2023-03-01 Regeneron Pharma Humanized mice possess a universal light chain
EP2757875B2 (en) 2011-09-19 2023-03-22 Kymab Limited Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
WO2013045916A1 (en) 2011-09-26 2013-04-04 Kymab Limited Chimaeric surrogate light chains (slc) comprising human vpreb
US9253965B2 (en) 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
GB201122047D0 (en) * 2011-12-21 2012-02-01 Kymab Ltd Transgenic animals
SG11201403326VA (en) 2011-12-20 2014-07-30 Regeneron Pharma Humanized light chain mice
WO2013116609A1 (en) * 2012-02-01 2013-08-08 Regeneron Pharmaceuticals, Inc. Humanized rodents that express heavy chains containing vl domains
GB2502127A (en) 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
US10251377B2 (en) 2012-03-28 2019-04-09 Kymab Limited Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
PT3597037T (pt) 2012-06-12 2021-06-01 Regeneron Pharma Animais não humanos humanizados com lócus de cadeia pesada de imunoglobulina restrito
SMT201800435T1 (it) 2013-02-20 2018-09-13 Regeneron Pharma Animali non umani con sequenze della catena pesante dell’immunoglobulina modificate riferimento incrociato a domande correlate
US9788534B2 (en) 2013-03-18 2017-10-17 Kymab Limited Animal models and therapeutic molecules
US9783618B2 (en) 2013-05-01 2017-10-10 Kymab Limited Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
US11707056B2 (en) 2013-05-02 2023-07-25 Kymab Limited Animals, repertoires and methods
US9783593B2 (en) 2013-05-02 2017-10-10 Kymab Limited Antibodies, variable domains and chains tailored for human use
ES2993142T3 (en) 2013-10-01 2024-12-23 Kymab Ltd Animal models and therapeutic molecules
BR112016021572A2 (pt) 2014-03-21 2017-10-03 Regeneron Pharma Métodos para preparar um animal não humano geneticamente modificado e para produzir proteínas de ligação, hibridoma, ácido nucleico, célula, e, proteína de ligação
ES2762640T3 (es) 2014-03-21 2020-05-25 Regeneron Pharma Proteínas VL de unión a antígeno que exhiben diferentes características de unión
EP3271403A1 (en) * 2015-03-19 2018-01-24 Regeneron Pharmaceuticals, Inc. Non-human animals that select for light chain variable regions that bind antigen
AU2016243052C1 (en) * 2015-04-03 2022-11-24 Dana-Farber Cancer Institute, Inc. Composition and methods of genome editing of B-cells
EP3440194A1 (en) * 2016-04-04 2019-02-13 ETH Zurich Mammalian cell line for protein production and library generation
MX2018014172A (es) 2016-05-20 2019-08-22 Regeneron Pharma Métodos para romper la tolerancia inmunológica usando múltiples arn guías.
CN110719732B (zh) * 2017-03-30 2022-11-18 犹他州立大学 表达蜘蛛丝的转基因蚕
SG11202003044SA (en) * 2017-12-05 2020-04-29 Regeneron Pharma Non-human animals having an engineered immunoglobulin lambda light chain and uses thereof
US20210051929A1 (en) * 2018-03-24 2021-02-25 Regeneron Pharmaceuticals, Inc. Genetically modified non-human animals for generating therapeutic antibodies against peptide-mhc complexes, methods of making and uses thereof
IL318469A (en) * 2018-06-14 2025-03-01 Regeneron Pharma Non-human animals capable of reorganizing transgenic DH-DH, and their uses
TW202229328A (zh) 2020-09-11 2022-08-01 美商再生元醫藥公司 抗原特異性抗體之鑑定及產生
JP2024500399A (ja) 2020-12-16 2024-01-09 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ヒト化Ｆｃアルファ受容体を発現するマウス
CN114645042A (zh) * 2020-12-18 2022-06-21 中国食品药品检定研究院 一种构建具有表达荧光素酶和红色荧光蛋白的重组巨噬细胞的转基因小鼠的方法
CN114196626A (zh) * 2022-02-16 2022-03-18 北京国卫生物科技有限公司 脐带间充质干细胞及其分离培养扩增方法
WO2025145264A1 (zh) * 2024-01-02 2025-07-10 江苏集萃药康生物科技股份有限公司 产生人源化抗体的动物模型及其构建方法

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6774279B2 (en) 1997-05-30 2004-08-10 Carnegie Institution Of Washington Use of FLP recombinase in mice
AU8470301A (en) * 2000-08-03 2002-02-18 Wim-Van Schooten Production of humanized antibodies in transgenic animals
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US7105348B2 (en) 2000-10-31 2006-09-12 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
CN101016543A (zh) * 2000-11-17 2007-08-15 罗切斯特大学 筛选编码抗原特异性免疫球蛋白分子或其抗原特异性片段的多核苷酸的方法
US7473557B2 (en) 2001-06-06 2009-01-06 Regeneron Pharmaceuticals, Inc. Method for targeting transcriptionally active loci
JP4408371B2 (ja) 2001-12-21 2010-02-03 トロンボジェニクス・ナムローゼ・フエンノートシャップ 生殖細胞系伝達能力を有する胚性幹（ｅｓ）細胞のインビトロの誘導および培養のための組成物
AU2003230741A1 (en) * 2002-03-22 2003-10-13 Origen Therapeutics Transgenic aves producing human polyclonal antibodies
MXPA06000562A (es) * 2003-07-15 2006-03-30 Therapeutic Human Polyclonals Loci de inmunoglobulina humanizada.
PL2767161T3 (pl) 2004-10-19 2018-09-28 Regeneron Pharmaceuticals, Inc. Sposób wytwarzania zwierzęcia homozygotycznego pod względem modyfikacji genetycznej
US20060117398A1 (en) * 2004-10-22 2006-06-01 Roland Buelow Suppression of endogenous immunoglobulin expression
WO2007117410A2 (en) * 2006-03-31 2007-10-18 Medarex, Inc. Transgenic animals expressing chimeric antibodies for use in preparing human antibodies
CA2661848C (en) * 2006-09-01 2015-02-03 Therapeutic Human Polyclonals, Inc. Enhanced expression of human or humanized immunoglobulin in non-human transgenic animals
WO2009026660A1 (en) * 2007-08-30 2009-03-05 Walter And Eliza Hall Institute Of Medical Research Dendritic cell marker and uses thereof
KR102339457B1 (ko) * 2007-09-26 2021-12-14 추가이 세이야쿠 가부시키가이샤 항체 정상영역 개변체
US7659842B2 (en) 2007-10-24 2010-02-09 Infineon Technologies Ag Quantization error reduction in PWM full-MASH converters
EP2669298A3 (en) * 2008-05-23 2014-02-26 Ablexis, LLC Single variable immunoglobulin domain comprising VL-DH-JL
ES2445193T3 (es) * 2008-06-27 2014-02-28 Merus B.V. Mamíferos no humanos productores de anticuerpos
EP2331689A4 (en) * 2008-08-29 2012-10-31 Symphogen As METHOD OF CLONING AVIAN ORIGIN ANTIBODIES
CA2983133A1 (en) * 2009-02-04 2010-08-12 Molecular Innovations Methods for screening candidate agents for modulating prorenin and renin, assays for detecting prorenin, and antibodies used therein
ES2948572T3 (es) * 2009-07-08 2023-09-14 Kymab Ltd Modelos de roedores y moléculas terapéuticas
RU2425880C2 (ru) * 2009-07-30 2011-08-10 Учреждение Российской академии наук Институт общей генетики им. Н.И. Вавилова РАН Способ получения трансгенных мышей
CA2802591A1 (en) * 2010-06-17 2011-12-22 Kymab Limited Animal models and therapeutic molecules
IL315833A (en) * 2010-08-02 2024-11-01 Regeneron Pharma Mice producing binding proteins containing VL regions
HUE024534T2 (hu) * 2011-02-25 2016-01-28 Regeneron Pharma ADAM6 egerek
IL273982B2 (en) * 2011-08-05 2023-03-01 Regeneron Pharma Humanized mice possess a universal light chain
SG11201403326VA (en) * 2011-12-20 2014-07-30 Regeneron Pharma Humanized light chain mice
WO2013116609A1 (en) * 2012-02-01 2013-08-08 Regeneron Pharmaceuticals, Inc. Humanized rodents that express heavy chains containing vl domains
PT3597037T (pt) * 2012-06-12 2021-06-01 Regeneron Pharma Animais não humanos humanizados com lócus de cadeia pesada de imunoglobulina restrito
CA3038720A1 (en) * 2016-11-04 2018-07-12 Regeneron Pharmaceuticals, Inc. Non-human animals having an engineered immunoglobulin lambda light chain locus

Also Published As

Publication number Publication date
KR20140123983A (ko) 2014-10-23
CN104202971B (zh) 2016-07-06
AU2013204758B2 (en) 2015-07-23
ES2753774T3 (es) 2020-04-14
JP2015505477A (ja) 2015-02-23
AU2015246154A1 (en) 2015-11-12
EP2809150B1 (en) 2019-09-18
EP2809150A1 (en) 2014-12-10
DK2809150T3 (da) 2019-12-09
US20170094955A1 (en) 2017-04-06
AU2013204758A1 (en) 2013-08-15
IL268675B (en) 2020-11-30
NZ627977A (en) 2016-06-24
RU2014133653A (ru) 2016-03-20
WO2013116609A1 (en) 2013-08-08
CY1124361T1 (el) 2022-07-22
MX2020003491A (es) 2022-10-25
HUE055610T2 (hu) 2021-12-28
CY1122419T1 (el) 2021-01-27
EP3597038A1 (en) 2020-01-22
EP3912465A1 (en) 2021-11-24
PL3597038T3 (pl) 2021-11-08
LT3597038T (lt) 2021-05-25
PT2809150T (pt) 2019-12-09
RU2018122695A3 (enExample) 2021-10-06
BR112014018843A2 (pt) 2017-07-04
AU2017251848B2 (en) 2020-02-20
AU2017251848A1 (en) 2017-11-16
CA2863175A1 (en) 2013-08-08
JP7525579B2 (ja) 2024-07-30
JP6942757B2 (ja) 2021-09-29
SG10201913428QA (en) 2020-03-30
JP2023014242A (ja) 2023-01-26
JP2023168590A (ja) 2023-11-24
SG11201404477YA (en) 2014-08-28
NZ810648A (en) 2025-11-28
IL261280B (en) 2019-08-29
JP2019170395A (ja) 2019-10-10
ME03611B (me) 2020-07-20
BR112014018843B1 (pt) 2024-02-20
PT3597038T (pt) 2021-05-10
MX373286B (es) 2020-05-20
AU2015246154B2 (en) 2017-11-23
SMT201900685T1 (it) 2020-01-14
NZ793447A (en) 2024-05-31
CN106117364A (zh) 2016-11-16
BR112014018843A8 (pt) 2019-01-29
SI2809150T1 (sl) 2019-11-29
MX2019002517A (es) 2019-06-17
ES2870703T3 (es) 2021-10-27
KR20190006029A (ko) 2019-01-16
JP2018075041A (ja) 2018-05-17
CN106117364B (zh) 2021-08-31
HRP20192218T1 (hr) 2020-03-06
NZ734504A (en) 2022-10-28
CN104202971A (zh) 2014-12-10
US20130212719A1 (en) 2013-08-15
RU2018122695A (ru) 2019-03-06
PL2809150T3 (pl) 2020-04-30
IL233827A0 (en) 2014-09-30
RU2770016C2 (ru) 2022-04-14
JP2021137030A (ja) 2021-09-16
US20210368751A1 (en) 2021-12-02
IL268675A (en) 2019-10-31
LT2809150T (lt) 2019-10-25
DK3597038T3 (da) 2021-06-28
RS62023B1 (sr) 2021-07-30
HRP20210987T1 (hr) 2021-09-17
NZ719228A (en) 2022-08-26
RS59699B1 (sr) 2020-01-31
SG10201606256TA (en) 2016-09-29
RU2664185C2 (ru) 2018-08-15
SI3597038T1 (sl) 2021-07-30
HUE046744T2 (hu) 2020-03-30
EP3597038B1 (en) 2021-04-21
IL261280A (en) 2018-10-31
JP6698718B2 (ja) 2020-05-27
JP7187615B2 (ja) 2022-12-12
HK1202771A1 (en) 2015-10-09

Similar Documents

Publication Publication Date Title
IL268675B (en) Humanized rodents expressing heavy chains comprising vl complexes
IL268674A (en) Rodents with humanized IL-7
ZA201407272B (en) Anti-baff-anti-il-17 bispecific antibodies
PL3058134T3 (pl) Pozakomórkowe polimery z granulowanego osadu ściekowego jako środki zaklejające
GB2511165B (en) Multi-sash closure system
SI2746185T1 (sl) Zaporni šarnir
ZA201306526B (en) Roll-open closure
AU342768S (en) Latch for lunchbox
GB201321568D0 (en) Chain stopper
ZA201301102B (en) Closure arrangement
AU346180S (en) Spout
GB201214914D0 (en) Eye cab